Ascend Laboratories appears in U.S. records for cephalexin, the prescription cephalosporin antibiotic historically associated with Keflex. Ascend Laboratories is named on U.S. cephalexin capsule and suspension records. An Ascend suspension label names Alkem Laboratories as manufacturer and Ascend as distributor, demonstrating that package identity and physical manufacture can differ. A label is a document about a specific product family; it is not a guarantee of current retail stock or a recommendation of one generic company over another.
This guide focuses on evidence about Ascend rather than repeating the generic cephalexin product overview. Its practical task is to identify capsule NDC families and 125 mg/5 mL or 250 mg/5 mL suspension, interpret the company role and determine what a pharmacist can verify on an actual prescription. Use the U.S. manufacturer index when comparing several company names.
For any prescription, check the active ingredient, product form, strength or concentration, pharmacist-confirmed NDC and written directions. An online pill image or DailyMed update cannot confirm what a particular pharmacy dispenses today. Cephalexin remains prescription-only, and differences in packaging do not authorize changes to treatment.
Ascend appears as a packager or distributor on specific cephalexin capsule and suspension records. One associated liquid label also names Alkem Laboratories as the manufacturer. Compare these exact role statements rather than using Ascend as a synonym for the plant that made every package.
For a medicine in hand, use the printed package and pharmacy receipt as the starting point; product listings describe a label family, while the dispensed NDC identifies the actual packaged item.
| Your next question | Relevant Core guide | What it covers |
|---|---|---|
| Verify generic category | Generic products | Understand approved forms |
| Compare other companies | Manufacturer index | Compare labeling roles |
| Identify capsules | Cephalexin capsules | Check strength and imprint |
| Review liquid products | Cephalexin suspension | See concentrations and preparation |
| Need pharmacy availability | Availability checks | Ask about the actual NDC |
The documented focus here is capsule NDC families and 125 mg/5 mL or 250 mg/5 mL suspension. The dose a patient should receive is determined by the prescription and medical context, not by which strength appears first in a manufacturer catalog.
The Ascend labels support exact suspension concentrations of 125 mg/5 mL and 250 mg/5 mL, and the capsule label includes multiple NDC families. Neither establishes local inventory. When the pharmacy offers a different dosage form, ask the dispensing pharmacist whether the order permits it. See forms and strengths for the broader product matrix.
Ascend’s product records contain multiple capsule NDC families, while its suspension product labels distinguish 125 mg/5 mL from 250 mg/5 mL. This is an example where “Ascend cephalexin” describes a labeler group rather than a single unit or concentration. A pharmacy quote needs the exact selected presentation.
DailyMed identifies label revisions, product codes and, where provided, application identifiers. FDA Orange Book information has a distinct role in checking approved products and therapeutic equivalence; a label publication date is not itself proof that a product newly launched or was delivered to retailers.
For Ascend, the public label itself provides a useful case study in tracing who labels, distributes and physically makes a prescription antibiotic. Record the exact source and date if using company data for a prescription or product question.
The Ascend suspension label includes specific prepared bottle amounts, and a later revision may affect how that product’s information is displayed. Those documented bottle sizes are not a prediction that a pharmacy can fill every volume on demand. A valid order, sourcing options and dispensing needs still govern the available quantity.
On an Ascend cephalexin package, the NDC identifies the specific listed drug or package presentation. The FDA emphasizes that the presence of an NDC is not proof of FDA approval. The Orange Book and drug labeling answer different questions from a wholesaler or retail inventory report.
Ask a pharmacist to compare the NDC on the dispensed package against the prescription’s ingredient, strength and dosage form. A listed NDC does not prove the pack is available at a particular pharmacy or that Ascend physically manufactured every repackaged unit.
Ascend may be the commercial name visible to the pharmacy even where a label identifies a separate physical manufacturer. For example, a suspension label names Alkem Laboratories for manufacture and Ascend for distribution. That division of work does not, by itself, indicate a product-quality problem.
To verify a package, first identify the role actually printed on that label, then compare it with the dispensed NDC and pharmacy record. This page does not claim that every cephalexin product sold under an Ascend-associated record comes from one manufacturing facility.
Capsule appearance can vary with the specific Ascend-associated NDC, lot and any permitted repackaging. Color and imprint comparisons are useful identifiers only when tied to the package label, not when inferred from a generic search image.
Before taking a capsule whose appearance differs from a prior refill, read the printed strength and imprint to the pharmacist. The pharmacist can compare the actual dispensed record with current official product identification information.
Ascend-associated cephalexin suspension documentation includes 125 mg/5 mL and 250 mg/5 mL product contexts. These are concentrations after correct pharmacy preparation; the same milliliter amount contains different quantities of antibiotic in the two strengths.
Confirm the exact prepared concentration and bottle volume shown on the dispensed label. Caregivers must use the supplied measuring device and pharmacy directions, never carry over a previous bottle’s mL instructions to a different concentration.
When a pharmacy can dispense an eligible therapeutically equivalent cephalexin product from a different labeler, it should check the active ingredient, dose form, strength, relevant Orange Book therapeutic-equivalence information and applicable prescription or state restrictions. Ascend labeling alone cannot authorize substitution.
A manufacturer change may alter appearance or excipients, but it does not mean the antibiotic class has changed. A different active ingredient, concentration or route is a separate clinical and pharmacy decision.
The existence of an Ascend label does not show whether an online or neighborhood pharmacy stocks that company’s product. Asking for a specific manufacturer may affect sourcing or turnaround time even when generic cephalexin is otherwise available.
Request a quote for the authorized product, including form, quantity and any coverage limitations, then verify current stock directly. Use the cost guide instead of using a company name as a price estimate.
Patients may notice Ascend on the bottle while an FDA or pharmacy information panel refers to a different company for manufacture. That is not by itself proof of a counterfeit or a problem; it should prompt verification of the labeled chain of responsibility. The pharmacist can match the NDC and inspect the original product documentation.
Products associated with Ascend carry the same core cephalexin antibiotic considerations: hypersensitivity history, important interactions, renal function where relevant and evaluation for serious antibiotic-associated diarrhea. A manufacturer-specific page does not override the prescribed clinical indication.
For dosing or serious symptoms, use the prescribing clinician and dispensing pharmacist. The patient’s actual package and instructions determine the selected form; a company page is not a patient-specific dosing reference.
Confirm the cephalexin active ingredient, the particular Ascend label, package NDC, exact form or concentration, application context when relevant and pharmacy instructions. Separate current dispensing information from historical or public database entries.
The Ascend labels support exact suspension concentrations of 125 mg/5 mL and 250 mg/5 mL, and the capsule label includes multiple NDC families. Neither establishes local inventory. The goal is reliable product identification—not a fabricated endorsement, a ranking of manufacturers, or a guarantee of present-day stock.
Yes. DailyMed includes a cephalexin label associated with Ascend Laboratories. Verify the particular form and the latest relevant record.
This page discusses capsule NDC families and 125 mg/5 mL or 250 mg/5 mL suspension. A product record does not establish that every pharmacy carries each presentation.
Not necessarily. Labeler, distributor, packager, application holder and physical manufacturing roles can differ; consult the specific labeling statements.
No public label proves real-time retail stock. A pharmacy must confirm whether it can supply a particular product.
An eligible therapeutically equivalent generic may be dispensable under state law and prescription instructions. Ask the pharmacist to verify the specific substitution.
No. FDA states that assignment of an NDC alone does not indicate approval; check applicable approval records separately.
There is no reliable universal price ranking. Pharmacy, product, quantity, insurance and cash-discount terms change the final amount.
Yes. Regardless of manufacturer, cephalexin remains a prescription antibiotic in the United States.